FDA Grants Breakthrough Status to MindMed's LSD Therapy Showing Promise for Treating Anxiety
• FDA grants breakthrough status to MindMed's LSD therapy for generalized anxiety disorder after positive Phase 2 trials • Single dose provided lasting anxiety relief; side effects were mild to moderate • Therapy must still go through standard FDA approval process, including Phase 3 trials • MindMed plans to meet with FDA soon and expand clinical program in second half of 2022 • Researcher calls Phase 2 trial findings "truly remarkable" for potential of LSD to treat anxiety